Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain
Abstract
Authors
C Rubio-Terrés J Orofino J Armas J Parra D Rubio-Rodríguez S Grau